Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results

Metabolic cardioprotection is an important part of treating patients with coronary heart disease (CHD). The most widely used drug in this group is trimetazidine. Its mechanism of action is based on fatty acids metabolism inhibition, glucose oxidation activation, intracellular ATP deficit prevention....

Full description

Bibliographic Details
Main Authors:	L. V. Kremneva, O. V. Abaturova, S. V. Shalaev
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2005-04-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	metabolic cardioprotection trimetazidine stable angina myocardial infarction heart failure myocardial revascularization
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/938

id	doaj-aa743dae61be4b2babd77f8dcde5cd19
record_format	Article
spelling	doaj-aa743dae61be4b2babd77f8dcde5cd192021-07-28T13:50:40Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252005-04-014299107653Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ resultsL. V. Kremneva0O. V. Abaturova1S. V. Shalaev2Tumen Cardiology Center, Cardiology Research Institute of Tomsk Scientific Center, Siberian Branch of the Russian Academy of Medical Science, TumenTumen Cardiology Center, Cardiology Research Institute of Tomsk Scientific Center, Siberian Branch of the Russian Academy of Medical Science, TumenTumen Cardiology Center, Cardiology Research Institute of Tomsk Scientific Center, Siberian Branch of the Russian Academy of Medical Science, TumenMetabolic cardioprotection is an important part of treating patients with coronary heart disease (CHD). The most widely used drug in this group is trimetazidine. Its mechanism of action is based on fatty acids metabolism inhibition, glucose oxidation activation, intracellular ATP deficit prevention. Numerous randomized, controlled clinical studies demonstrated trimetazidine antiischemic efficacy, similar to that for beta-adrenoblockers or calcium antagonists. Trimetazidine improves myocardial contractility, reduces clinical manifestations of heart failure. The medication beneficially influences ischemia-associated myocardial dysfunction: stunning, hybernation, preconditioning. Trimetazidine is recommended for treating patients with stable angina and ischemic left ventricular dysfunction, in combination with other drugs. Perspectives of trimetazidine therapy in myocardial revascularization and acute myocardial infarction should be examined in future trials.https://cardiovascular.elpub.ru/jour/article/view/938metabolic cardioprotectiontrimetazidinestable anginamyocardial infarctionheart failuremyocardial revascularization
collection	DOAJ
language	Russian
format	Article
sources	DOAJ
author	L. V. Kremneva O. V. Abaturova S. V. Shalaev
spellingShingle	L. V. Kremneva O. V. Abaturova S. V. Shalaev Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results Кардиоваскулярная терапия и профилактика metabolic cardioprotection trimetazidine stable angina myocardial infarction heart failure myocardial revascularization
author_facet	L. V. Kremneva O. V. Abaturova S. V. Shalaev
author_sort	L. V. Kremneva
title	Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results
title_short	Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results
title_full	Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results
title_fullStr	Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results
title_full_unstemmed	Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results
title_sort	trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results
publisher	«SILICEA-POLIGRAF» LLC
series	Кардиоваскулярная терапия и профилактика
issn	1728-8800 2619-0125
publishDate	2005-04-01
description	Metabolic cardioprotection is an important part of treating patients with coronary heart disease (CHD). The most widely used drug in this group is trimetazidine. Its mechanism of action is based on fatty acids metabolism inhibition, glucose oxidation activation, intracellular ATP deficit prevention. Numerous randomized, controlled clinical studies demonstrated trimetazidine antiischemic efficacy, similar to that for beta-adrenoblockers or calcium antagonists. Trimetazidine improves myocardial contractility, reduces clinical manifestations of heart failure. The medication beneficially influences ischemia-associated myocardial dysfunction: stunning, hybernation, preconditioning. Trimetazidine is recommended for treating patients with stable angina and ischemic left ventricular dysfunction, in combination with other drugs. Perspectives of trimetazidine therapy in myocardial revascularization and acute myocardial infarction should be examined in future trials.
topic	metabolic cardioprotection trimetazidine stable angina myocardial infarction heart failure myocardial revascularization
url	https://cardiovascular.elpub.ru/jour/article/view/938
work_keys_str_mv	AT lvkremneva trimetazidineincoronaryheartdiseasepatientsmechanismofactionandcontrolledtrialsresults AT ovabaturova trimetazidineincoronaryheartdiseasepatientsmechanismofactionandcontrolledtrialsresults AT svshalaev trimetazidineincoronaryheartdiseasepatientsmechanismofactionandcontrolledtrialsresults
_version_	1721271489154514944

Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results

Similar Items